SEC Form S-8 filed by Wave Life Sciences Ltd.
As filed with the Securities and Exchange Commission on November 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
| Singapore | 98-1356880 | |
| (State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) | |
| 7 Straits View #12-00, Marina One East Tower Singapore |
018936 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended
(Full title of the plan)
CT Corporation
155 Federal Street, Suite 700
Boston, MA 02110
(617) 757-6400
(Name, address and telephone number, including area code, of agent for service)
Copies to:
| William C. Hicks, Esq. John T. Rudy, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 (617) 542-6000 |
Linda Rockett, Esq. Senior Vice President, General Counsel Wave Life Sciences Ltd. c/o 733 Concord Avenue Cambridge, MA 02138 (617) 949-2900 |
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This registration statement registers an aggregate of 5,000,000 additional ordinary shares of Wave Life Sciences Ltd. (the “Registrant”) reserved under the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended (the “2021 Plan”), representing an increase of 5,000,000 ordinary shares reserved under the 2021 Plan effective August 6, 2024. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (File No. 333-259196) relating to an employee benefit plan is effective. The information contained in the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on August 31, 2021 (File No. 333-259196) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:
(a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 6, 2024 (File No. 001-37627) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Amendment No. 1 to the Annual Report on Form 10-K/A filed on April 29, 2024 (File No. 001-37627) under the Exchange Act.
(b) The portions of the Registrant’s definitive proxy statement on Schedule 14A filed on June 21, 2024 (File No. 001-37627) that are deemed “filed” with the Commission under the Exchange Act.
(c) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 filed on May 10, 2024 (File No. 001-37627) under the Exchange Act, the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed on August 8, 2024 (File No. 001-37627) under the Exchange Act, and the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 filed on November 12, 2024 (File No. 001-37627) under the Exchange Act.
(d) The Registrant’s Current Reports on Form 8-K filed on January 4, 2024, June 25, 2024, August 12, 2024, September 24, 2024, September 26, 2024, October 15, 2024, October 16, 2024, and October 30, 2024 (File No. 001-37627) under the Exchange Act (in each case, except for information contained therein which is furnished rather than filed).
(e) The description of the Registrant’s Ordinary Shares contained in the Registrant’s Registration Statement on Form 8-A filed on November 9, 2015 (File No. 001-37627) under the Exchange Act, including any amendment or report filed for the purpose of updating such description.
(f) All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 8. EXHIBITS.
| * | Previously filed as Exhibit 3.2 to Amendment No. 5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on November 10, 2015 and incorporated herein by reference. |
| ** | Previously filed as Exhibit 4.1 to Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on November 6, 2015 and incorporated herein by reference. |
| *** | Previously filed as Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-207379), filed with the Commission on October 9, 2015 and incorporated herein by reference. |
| **** | Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 9, 2018 and incorporated herein by reference. |
| ***** | Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on August 15, 2016 and incorporated herein by reference. Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Commission. |
| ****** | Previously filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on May 9, 2018 and incorporated herein by reference. |
| ******* | Previously filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on May 9, 2018 and incorporated herein by reference. |
| ******** | Previously filed as Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-37627), filed with the Commission on March 23, 2023 and incorporated herein by reference. |
| ********* | Previously filed as Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-37627), filed with the Commission on March 23, 2023 and incorporated herein by reference. |
| ********** | Previously filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on June 14, 2022 and incorporated herein by reference. |
| *********** | Previously filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on September 26, 2024 and incorporated herein by reference. |
| + | Previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37627), filed with the Commission on August 12, 2024 and incorporated herein by reference. |
| ++ | Previously filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference. |
| +++ | Previously filed as Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference. |
| ++++ | Previously filed as Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference. |
| +++++ | Previously filed as Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37627), filed with the Commission on November 10, 2021 and incorporated herein by reference. |
| @ | Management contract or compensatory plan. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on November 12, 2024.
| Wave Life Sciences Ltd. | ||
| By: | /s/ Paul B. Bolno, M.D., MBA | |
| Paul B. Bolno, M.D., MBA | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul B. Bolno, M.D., MBA and Kyle Moran, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
Title |
Date | ||
| /s/ Paul B. Bolno, M.D., MBA Paul B. Bolno, M.D., MBA |
President, Chief Executive Officer and Director (Principal Executive Officer) |
November 12, 2024 | ||
| /s/ Kyle Moran Kyle Moran |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
November 12, 2024 | ||
| /s/ Christian Henry Christian Henry |
Chairman of the Board | November 12, 2024 | ||
| /s/ Mark H. N. Corrigan, M.D. Mark H. N. Corrigan, M.D. |
Director | November 12, 2024 | ||
| /s/ Peter Kolchinsky, Ph.D. Peter Kolchinsky, Ph.D. |
Director | November 12, 2024 | ||
| /s/ Adrian Rawcliffe Adrian Rawcliffe |
Director | November 12, 2024 | ||
| /s/ Ken Takanashi, MBA, CPA Ken Takanashi, MBA, CPA |
Director | November 12, 2024 | ||
| /s/ Aik Na Tan Aik Na Tan |
Director | November 12, 2024 | ||
| /s/ Gregory L. Verdine, Ph.D. Gregory L. Verdine, Ph.D. |
Director | November 12, 2024 | ||
| /s/ Heidi L. Wagner, J.D. Heidi L. Wagner, J.D. |
Director | November 12, 2024 | ||